Rafael Holdings Completes Pre-NDA Meeting, Targets H2 2026 for Trappsol® Cyclo™ NDA Submission & Topline Data
RFL has more than doubled off its 52-week low of $1.12.
Summary
Rafael Holdings provided a key regulatory update for its lead drug Trappsol® Cyclo™, confirming the completion of a pre-NDA meeting and reiterating plans for NDA submission and topline data in the second half of 2026.
Key Events · Product Development and Regulatory · RFL
-
Pre-NDA Meeting Completed
Rafael Holdings announced the completion of a pre-NDA meeting for its lead drug, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC).
-
Regulatory Submission Timeline Confirmed
The company expects to submit the New Drug Application (NDA) and release topline data for Trappsol® Cyclo™ in the second half of 2026.
-
Phase 3 Trial Progress
This update follows the previously announced completion of the Last Patient Last Visit (LPLV) in the pivotal Phase 3 TransportNPC clinical trial in June 2026.
Analysis · RFL · Life Sciences
This 8-K announces the completion of a crucial pre-NDA meeting with regulatory authorities for Trappsol® Cyclo™ and confirms the timeline for NDA submission and topline data in the second half of 2026. This follows the recent completion of the last patient visit in the Phase 3 trial, marking significant progress towards potential commercialization for their lead rare disease drug.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RFL was trading at $2.57 on NYSE in the Life Sciences sector, with a market capitalization of approximately $127.4M. The 52-week trading range was $1.12 to $3.96. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.